Compass Pathways: Early Bull Case — Buy the Clinical Win, Manage the Binary Risk
COMPASS Pathways (CMPS) is a clinical-stage psychedelic biotech that just moved from speculative to actionable following positive late-stage data and a heavy-volume breakout. The market now prices a near-$900M market cap into a pathway toward commercial psilocybin therapy; this trade idea targets the next leg up while explicitly protecting for regu…